U.S. HCV Competition Increases As Bristol, AbbVie Get Same-Day Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s Daklinza gets FDA nod for tandem therapy with Sovaldi in genotype 3 patients; AbbVie combo Technivie approved to treat non-cirrhotic genotype 4 patients.